This article reviews case series and trials that evaluated extracorporeal membrane oxygenation (ECMO) for respiratory failure and describes patient and circuit management in the modern era of ECMO support.
INTRODUCTION
The acute respiratory distress syndrome (ARDS) is a severe lung disease, whose associated mortality rate remains high [1] [2] [3] . The most severe forms of the disease, for which hypoxemia resulting from the pulmonary involvement is the most profound, have an even more dismal prognosis, with mortality that may well exceed 60% [4 & ]. In these situations, some centers proposed establishing an extracorporeal circuit, combining a centrifugal pump and a membrane oxygenator, assuring extracorporeal pulmonary assistance (oxygenation and CO 2 removal from the blood), or extracorporeal membrane oxygenation (ECMO) [5, 6] , to minimize the trauma caused by mechanical ventilation and to allow the lungs to rest while recovering. However, trials evaluating ECMO for this indication over the past few decades [7, 8] did not demonstrate benefit because of the prolonged interval between the onset of the disease and the installation of assistance, the poor oxygenation and CO 2 -removal capacities of the devices used and the high rate of complications linked to the apparatus (significant bleeding resulting from intense anticoagulation required due to the poor biocompatibility of the circuits).
In recent years, pivotal progress has been made in the construction of ECMO circuits, rendering them to be more biocompatible, to perform better and to last longer. The encouraging results of the efficacy and economic assessment of conventional ventilatory support versus ECMO for severe adult respiratory failure (CESAR) trial [9 && ] and good outcomes of patients who received ECMO as rescue therapy during the recent H1N1 influenza pandemic [10,11 && ], in which the latest generation of ECMO was used, reignited interest in ECMO for severe ARDS.
This article reviews case series and trials that evaluated ECMO for respiratory failure and describes patient and circuit management in the modern era of ECMO support.
HISTORICAL CASE SERIES OF EXTRACORPOREAL MEMBRANE OXYGENATION FOR ACUTE RESPIRATORY DISTRESS SYNDROME
In 1968, Kolobow et al. [12] designed the first membrane oxygenator for prolonged extracorporeal circulation. Hill et al. [13] described the first use of ECMO in 1971 for respiratory insufficiency in a 24-year-old polytrauma patient who benefited from 75 h of extracorporeal circulation, before being weaned off the machine with a favorable outcome. Several retrospective cohort studies have since been published [14] [15] [16] [17] [18] . The largest retrospective study evaluating ECMO for patients with severe ARDS was reported by Bartlett's group at the University of Michigan. They observed 52% survival of their 255 adult patients treated with ECMO between 1989 and 2004 [19, 20] . Other retrospective series also reported good survival (50-60%) of patients who had received ECMO assistance [14, 17, 18, 21] .
More recently, the collaborative Australian and New Zealand Intensive Care Society group reported on the experience in Australia and New Zealand with ECMO during the 2009 Influenza A (H1N1) pandemic flu [11 && ]. Among the 68 patients who received ECMO for flu-induced refractory ARDS, 75% survived [22] . Importantly, patients had signs of extremely severe disease at the time of ECMO implantation: a median P a O 2 /F i O 2 of 56 mmHg, despite a median positive end-expiratory pressure (PEEP) set at 18 cmH 2 O and median Murray score of 3.8.
RESULTS OF RANDOMIZED TRIALS OF EXTRACORPOREAL MEMBRANE OXYGENATION FOR ACUTE RESPIRATORY DISTRESS SYNDROME
The first multicenter, randomized trial to evaluate ECMO for ARDS was conducted by the National Institutes of Health in the United States in the 1970s on 90 patients with severe ARDS refractory to conventional ventilation techniques [7] . Patient survival in that trial was extremely low (<10%) and no improvement with ECMO was demonstrated. However, that study suffered from major methodological limitations. For example, the mode of ECMO support was only veno-arterial and when no improvement was observed after 5 days, ECMO was removed, which precluded the possibility of late clinical improvement. Because the ECMO group did not receive lung-protective ventilation, severe complications related to barotrauma occurred and since ECMO circuitry was not heparin-coated at that time, a very high percentage of patients had severe hemorrhagic complications due to excessive anticoagulation.
In the 1990s, Morris et al. [8] in Utah conducted another randomized, controlled trial, which was a single-center study using a device eliminating CO 2 . The study was stopped for futility after only 40 patients had been enrolled, and once again, the results did not advocate the use of this form of respiratory assistance.
The most recent trial (CESAR) was conducted in the United Kingdom from 2001 to 2006 [9 && ]. The patients randomized to receive ECMO support were transferred to a single center (Glenfield, Leicester), whereas the patients randomized to the control group were treated conventionally at designated treatment centers. Mortality or severe disability 6 months after randomization, the primary endpoint, was lower for the 90 patients randomized to the ECMO group (37 vs. 53%, P ¼ 0.03). However, that trial had two limitations that merit attention. First, 22 patients randomized to the ECMO arm did not receive ECMO (died before or during transport, improved with conventional management at the
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referral center or had a contraindication to heparin). The other major methodological problem is the absence of a standardized protocol for mechanical ventilation in the control group, for which it was merely recommended that the treating physicians adopt a strategy of lung-protective ventilation without further specifications.
INDICATIONS FOR EXTRACORPOREAL MEMBRANE OXYGENATION IN ACUTE RESPIRATORY FAILURE
ECMO support has been proposed for patients with ARDS refractory to conventional mechanical ventilation, and in other severe conditions such as lung trauma [23] , severe asthma [24] , pulmonary emboli [25] or patients with chronic lung disease awaiting lung transplantation [26] .
According to the extracorporeal life support organization (ELSO), 'ECMO initiation should be considered in hypoxic respiratory failure when the risk of mortality is 50% or greater, identified by P a O 2 /F i O 2 less than 150 mmHg on F i O 2 greater than 90% and/or Murray score 2-3, and is indicated when this risk exceeds 80%, that is when P a O 2 /F i O 2 is less than 80 on F i O 2 greater than 90% and Murray score is 3-4' [27] . Also, no absolute contraindications to ECMO were specified by this group, mechanical ventilation for severe ARDS for more than 7 days, major immunosuppression and recent CNS hemorrhage were considered to be associated with poor outcomes despite ECMO.
However, more strict criteria were proposed when the H1N1 pandemic emerged in the spring of 2009. In Australia, the New South Wales department of health in its guidelines for ECMO initiation, recommended immediate consultation for veno-venous ECMO in case of refractory hypoxemia (P a O 2 /F i O 2 <60 mmHg) or hypercarbia (P a CO 2 >100 mmHg, with P a O 2 /F i O 2 <100) [28] . Contraindications to ECMO were significant preexisting comorbidities, such as irreversible neurological condition, cirrhosis with ascites, encephalopathy or history of variceal bleeding, active and rapidly fatal malignancy, HIV infection, weight less than 120 kg, pulmonary hypertension and cardiac arrest. Similarly, the French REVA (réseau européen de recherche en ventilation artificielle) group proposed that the indications for ECMO in cases of refractory and persistent hypoxemia defined by P a O 2 /F i O 2 less than 50 mmHg, despite high PEEP (10-20 cmH 2 O) and high F i O 2 (>80%) ventilation or if plateau pressure was at least 35 cmH 2 O, despite Vt reduction to 4 ml/kg. Severe comorbidities and multiple organ failure (SOFA score >15) were considered contraindications to the use of ECMO for this group [29] .
ORGANIZATION OF AN EXTRACORPOREAL MEMBRANE OXYGENATION RETRIEVAL TEAM
Patients with severe ARDS who may be considered for transport from smaller or regional centers to tertiary centers with ECMO capabilities are often too sick to be safely transported without ECMO support. Indeed, in the CESAR trial conducted in the United Kingdom [9 && ], in which ECMO could be initiated only at the ECMO referral center in Leicester, five patients randomized to the ECMO group died before or during transport. Therefore, organization of a mobile ECMO retrieval team appears necessary to provide mobile ECMO support to smaller urban and regional hospitals [30] [31] [32] [33] . Such programs have been developed by many active ECMO centers worldwide [34, 35] . In Australia, 56% of the patients who received ECMO for H1N1-associated severe ARDS were transferred an average of 380 km from smaller or regional centers on ECMO without death or major complication [35] .
CANNULATION AND MODE OF EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT
Peripheral veno-venous ECMO should be the modality of choice for severe hypoxic respiratory failure wherein no major cardiac dysfunction exists. Indeed, use of peripheral veno-arterial ECMO in the presence of adequate cardiac function may cause severe hypoxia in the upper part of the body (brain and heart) in the setting of a severe pulmonary shunt. Therefore, echocardiography should be performed before veno-venous ECMO placement to identify severe left ventricular dysfunction, which might necessitate the use of venoarterial ECMO. Alternatively, right ventricular dysfunction secondary to ARDS-induced pulmonary hypertension is effectively treated by venovenous ECMO.
Peripheral cannulation should be strictly percutaneous by Seldinger technique, which can be rapidly performed by nonsurgical staff and remotely without the need for specialized surgical equipment, requires no skin suturing, reduces bleeding and allows simple decannulation when ECMO has been weaned. The use of vascular ultrasound before and during the procedure enables immediate confirmation of venous vessel access, guidewire identification in the right atrium to exclude coiling in proximal vessels and optimization of cannulae positioning to reduce recirculation.
VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION CIRCUIT SETTINGS AND MANAGEMENT
Vessel cannulation for veno-venous ECMO can be configured in several ways. In the femoro-jugular approach, a single large multiperforated drainage cannula is inserted in the femoral vein and advanced to the cavo-atrial junction. The return cannula is a single-stage catheter inserted in the right internal jugular vein to the superior vena cava (SVC). In the bi-femoral-jugular setting, drainage cannulae are positioned in both the SVC and inferior vena cava (IVC) from the jugular and femoral veins and a femoral return cannula is advanced to the right atrium. Alternatively, a single bicaval dual-lumen cannula (Avalon Elite) can be inserted via the right jugular vein and positioned to allow drainage from the IVC and SVC and return via a second lumen in the right atrium.
Catheter size and the number of drainage holes in the inflow cannula will determine maximal flow in the ECMO circuit. Depending on patient size, cardiac output, oxygen consumption and lung shunt, circuit blood flow between 4 and 7 l/min will typically be required to achieve arterial oxygen saturations greater than 85%, while maintaining well tolerated lung ventilation. As the degree of recirculated oxygenated blood can limit oxygenation in veno-venous ECMO, it is of utmost importance to ascertain that the tip of the return cannula is positioned away from that of the inflow cannula. It has also been shown that recirculation is reduced by configuring the veno-venous ECMO circuit to access blood from the vena cava and return to the right atrium (cavo-atrial flow) [36] . The bicaval duallumen cannula typically allows minimal blood recirculation.
If venous return to the draining ECMO cannula is insufficient for the degree of pump suction, negative pressure will increase on the drainage side, 'suck-down' will occur and circuit blood flow will be impeded. This situation must be identified and rectified quickly (first reducing pump speed then compensate for hypovolemia, if present) to prevent cavitation, hemolysis and potential vascular injury.
A gaseous air-oxygen mixture supplied to the oxygenator maintains the diffusion gradients for oxygen delivery and CO 2 removal. It can be composed of pure oxygen (100% F i O 2 ) or of an airÀoxygen mixture that will be adjusted to obtain P a O 2 greater than 55 mmHg and/or arterial oxygen saturation greater than 88%. The gas flow rate through the membrane will determine the partial pressure of CO 2 in the postoxygenator blood and its rate is chosen to achieve a desired P a CO 2 in the patient's arterial blood.
The ECMO circuit should be monitored several times daily by the medical and nursing team caring for the patient and at least once every 24 h by a perfusionist or other ECMO specialist. Circuit and cannula surveillance is intended to verify the correct functioning of the device and identify evolving complications early, including fibrin deposits or clots on the ECMO membrane, clots in the cannulas or pump, bleeding, signs of inflammation or infection at the cannula insertion sites, unexpected drops in ECMO outflow or the appearance of clinical or biochemical signs of intravascular hemolysis. If any of these complications occur, a combined multidisciplinary consultation should be conducted to establish the best therapeutic approach.
VENTILATOR SETTINGS UNDER VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION
Settings of mechanical ventilation for patients on veno-venous ECMO should minimize ventilatorassociated lung injury and permit higher degrees of protective lung ventilation. High PEEP levels (>10 cmH 2 O) should be maintained to prevent further lung collapse after the institution of ECMO. Blood oxygenation and decarboxylation through the ECMO circuit also allows tidal volume reduction to limit plateau pressure (suggested Pplat <25 cmH 2 O). In the most severe cases, alterations in lung compliance may be associated with negligible tidal volumes (<50 ml). F i O 2 on the ventilator should be reduced to the minimal value to keep arterial saturation greater than 85%.
ANTICOAGULATION MANAGEMENT ON VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION
As bleeding complications remain more problematic than thrombosis during veno-venous ECMO and because current generation circuits and oxygenators are heparin-coated, or coated with a biocompatible material, systemic anticoagulation should be titrated to very low levels. In ECMO patients who are not bleeding, targets are in the range of 45-60 s for aPTT and 0.2-0.3 IU/ml for heparinemia (anti-Xa activity). As transfusion of blood products might cause specific lung injuries [37] , the hemoglobin threshold for red cell transfusion should be 7-8 g/dl (some centers consider increasing to 10 g/dl if persistent hypoxemia) and platelet transfusion should be discouraged except when severe thrombocytopenia is accompanied by bleeding. Aspirin may be prescribed, at a platelet-antiaggregating dose, when the platelet count is greater than 100 g/l and in the absence of bleeding. Should severe bleeding occur that is not immediately controllable by specific treatment, antiplatelet drugs and heparin should be discontinued.
GENERAL THERAPEUTIC MEASURES ON VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION
Neuromuscular blocking agents may be used early after ECMO implantation in patients with S a O 2 less than 80% despite ECMO [38] . Sedation and analgesia, when not on neuromuscular blockers, should be titrated to the lowest dose possible to ensure comfort and prevent inadvertent dislodging of the ECMO cannulas. In patients for whom prolonged respiratory support is anticipated, early tracheostomy to facilitate patient comfort and ease of care might be performed [39, 40] . Diuresis to dry weight should be attempted early in the management of these ARDS patients [41] . However, volume expansion may be needed at the initial phase of the disease, because of associated septic shock or when hypovolemia might severely compromise blood blow and oxygenation through the ECMO circuit. When the patient is on minimal doses of pressors due to sedation, any effort should be made to achieve a net negative fluid balance, either with diuretics or with continuous renal replacement therapy, which can easily be performed by connecting the machine to the ECMO circuit.
WEANING VENO-VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT
Weaning of veno-venous ECMO should be considered when pulmonary function has improved as indicated by higher lung compliance (increasing tidal volumes on pressure controlled ventilation), resolving lung infiltrates and improvement in arterial PCO 2 and PO 2 . Mechanical ventilation should be set to lung-protective levels of support (e.g. tidal volume 6 ml/kg, plateau pressure <30 cmH 2 O, PEEP 8-12 cm H 2 O, F i O 2 0.6). Then the fresh gas flow to the oxygenator can be switched off while maintaining previous blood flow through the circuit. If the patient remains stable and adequately ventilated after a few hours of observation, and if echocardiography reveals no evidence of severe acute cor pulmonale ECMO cannulae can be simply pulled out. Other methods of weaning include gradual decreasing of the level of ECMO support.
CONCLUSION
Recently, there have been important technological improvements in ECMO circuitry, pump and oxygenator design. The latest generation of ECMO systems is simpler, safer, requires less anticoagulation and is associated with fewer bleeding complications.
Although recent studies suggested that venovenous ECMO might improve the outcomes of patients with ARDS, indications for ECMO use remain controversial [42] [43] [44] . Because the CESAR study was criticized for methodological limitations, new trials evaluating the impact of ECMO in severe respiratory failure are needed before widespread adoption of this technique. The international multicenter randomized extracorporeal membrane oxygenation for severe acute respiratory distress syndrome (EOLIA) trial will test the efficacy of early veno-venous ECMO in ARDS with tight control of mechanical ventilation in the control group, initiation of ECMO prior to transportation to ECMO centers and the use of ECMO in every patient randomly assigned to receive it [45] .
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